Dr. Michael Rieder

M Rieder

Office: B1-138, Victoria Hospital
Phone: 519.685.8500 ex58293
Fax: 519.685.8156
E-mail: Michael.Rieder@schulich.uwo.ca

MD Saskatchewan
Ph.D Toronto
Fellowship, Paediatric Emergency Medicine (Toronto)
Fellowship, Clinical Pharmacology (Toronto)

My research interests involve mechanistic studies of serious adverse drug reactions with a specific focus on drug hypersensitivity. Our group is working on determining the relative contributions of metabolism and immune response in the development of drug hypersensitivity to a number of drugs including commonly used antibiotics, anti-epilepsy drugs and chemotherapeutic agents. More recently we are investigating how genetically determined variations in drug metabolism, immune response, drug transport and cellular repair determine risk for serious adverse events to chemotherapy for childhood cancer. Our laboratory also has a long-standing interest in steroid biology and the impact of stress on corticosteroid production. We are also involved in a series of clinical studies to define optimal therapy for children in acute and emergency care settings. More recent areas of focus in our laboratory are studies on point of care diagnostics for food and drug safety and in the development of wireless sensor systems for the evaluation of pharmacological responses.

Selected Publications

171. Poonai N, Bhullar G, Lin K, Papini A, Mainprize D, Howard J, Teefy J, Bale M, Langford C, Lim R, Stitt L, Rieder MJ, Ali S. Oral administration of morphine versus ibuprofen to manage postfracture pain in children: a randomized trial. CMAJ. 186(18):1358-63.

172. Koren G, Rieder M. Measuring oral bioavailability of tacrolimus. Pediatr Transplant. PMID: 25250966 (2014 Nov); 18(7):656-7.

173. Sawa K, Yazdani A, Rieder MJ, Filler G. Propanolol therapy for infantile hemangioma is less toxic but longer in duration then corticosteroid therapy. Can J Plast Surg 2014; 22: 233-36.

174. Friedman JN, Rieder MJ, Walton JM; Canadian Paediatric Society, Acute Care Committee, Drug Therapy and Hazardous Substances Committee. Bronchiolitis: Recommendations for diagnosis, monitoring and management of children one to 24 months of age. Paediatr Child Health 2014;19(9):485-98.

175. Poonai N, Paskar D, Konrad SL, Rieder M, Joubert G, Lim R, Golozar A, Uledi S, Worster A, Ali S. Opioid analgesia for acute abdominal pain in children: A systematic review and meta-analysis.Acad Emerg Med 2014;21(11):1183-92.

189. Rieder M. Pharmacogenomics in children. Methods Mol Biol 2014;1175:687-707.

177. Kim SS, Michelsons S, Creber K, Rieder MJ, Hamilton DW. Nifedipine and phenytoin induce matrix synthesis, but not proliferation, in intact human gingival connective tissue ex vivo. J Cell Commun Signal (in-press).

178. Chitayat D, Matsui D, Amitai Y, Kennedy D, Vohra S, Rieder M, Koren G. Folic acid supplementation for pregnant women and those planning pregnancy – 2015 update. J Clin Pharmacol (in-press).

179. Aminkeng F, Bhavsar AP, Visscher H, Rassekh SR, Li Y, Lee JW, Brunham LR, Caron HN, van Dalen EC, Kremer LC, van der Pal HJ, Amstutz U, Rieder MJ, Bernstein D, Carleton BC, Hayden MR, Ross CJ; Canadian Pharmacogenomics Network for Drug Safety Consortium. A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer. Nat Genet 2015 Sep;47(9):1079-84.

180. Visscher H, Rassekh SR, Sandor GS, Caron HN, van Dalen EC, Kremer LC, van der Pal HJ, Rogers PC, Rieder MJ, Carleton BC, Hayden MR, Ross CJ; CPNDS consortium. Genetic variants in SLC22A17 and SLC22A7 are associated with anthracycline-induced cardiotoxicity in children. Pharmacogenomics 2015 Jul;16(10):1065-76.

181. Brouwer K, Aleksunes LM, Brandys B, Giacoia GP, Knipp G, Lukacova V, Meibohm B, Nigam SK, Rieder M, de Wildt SN; Pediatric Transporter Working Group. Human ontogeny of drug transporters: Review and recommendations of the Pediatric Transporter Working Group. Clin Pharmacol Ther 2015 Sep;98(3):266-87.

184. Smy L, Shaw K, Smith A, Russell E, Van Uum S, Rieder M, Carleton B, Koren G. Hair cortisol as a novel biomarker of HPA suppression by inhaled corticosteroids in children. Pediatr Res 2015 Jul;78(1):44-7.

Fraught LN, Greff MJ, Rieder MJ, Koren GDrug-induced acute kidney injury in children. J Clin Pharmacol. 2015 Oct;80(4):901-9.

Rieder M, Ferro A. Adverse drug reactions. Br J Clin Pharmacol. 2015 Oct;80(4):613-4.